Selumetinib in the treatment of non-small-cell lung cancer

Reyes Bernabe, Ana Patrao, Louise Carter, Fiona Blackhall, Emma Dean

Research output: Contribution to journalArticlepeer-review

195 Downloads (Pure)


The RAS–RAF–MEK–ERK pathway regulates processes involved in the proliferation and survival of cells. KRAS mutations, prevalent in approximately 30% of patients with non-small-cell lung cancer (NSCLC), result in constitutive activation of the pathway. Selumetinib (AZD6244, ARRY-142886) is a potent and selective inhibitor of MEK1/2 which has demonstrated significant efficacy in combination with docetaxel in patients with KRAS mutant pretreated advanced NSCLC. Several trials in combination with other chemotherapy and targeted therapy regimens in lung cancer are ongoing. We review the development of selumetinib in patients with NSCLC, summarize the pharmacodynamic, pharmacokinetic and tolerability characteristics, and the available clinical trial data to understand the role of selumetinib in the treatment of NSCLC.

Original languageEnglish
JournalFuture Oncology
Early online date28 Jul 2016
Publication statusPublished - 2016

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Selumetinib in the treatment of non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this